Ivabradine in Patients With Congestive Heart Failure

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 1, 2020

Primary Completion Date

February 1, 2021

Study Completion Date

February 5, 2021

Conditions
Congestive Heart Failure
Interventions
DRUG

Ivabradine Oral Tablet

Ivabradine 5 mg twice daily and doses (2.5, 5, 7.5 mg) were to be adjusted upwards or downwards at every visit according to HR at rest and tolerability plus their standard treatment.

DRUG

Blacebo plus standard treatment

Blacebo plus standard treatment

Trial Locations (1)

31527

Tanta University Hospital, Tanta

All Listed Sponsors
lead

Damanhour University

OTHER

NCT04448899 - Ivabradine in Patients With Congestive Heart Failure | Biotech Hunter | Biotech Hunter